If you have been reading about analytical verification and want a single page that covers the useful parts, this is it: definitions, context, how it is studied, and the questions that come up repeatedly.
Last reviewed on 2026-02-05. Where a claim depends on a specific study, the study is described rather than over-claimed.
Pharmacologically, melanotan-2 behaves as a non-selective agonist across the melanocortin receptor family. Binding at MC1R on dermal melanocytes promotes eumelanin synthesis, which underlies the tanning response described in early human work. Activity at the centrally expressed MC4R receptor is associated with reported effects on appetite and erectile function. Because the peptide does not discriminate strongly among receptor subtypes, attributing any single observed effect to one receptor pathway is generally not possible without selective antagonists or receptor knockout models.
Research interest has centred on photoprotection and pigmentation, with a smaller body of work on appetite and sexual function. Published human data remain limited to small, frequently uncontrolled studies, and the compound has never received marketing approval from a national medicines regulator. Most laboratory work treats it as a pharmacological tool for probing melanocortin signalling in cell culture or animal models. Whether pigmentation changes observed in people translate into measurable protection against ultraviolet-induced DNA damage remains an open question.
Because the substance circulates mainly through informal markets, verification is a recurring theme in technical discussion. Independent analyses have found that labeled content and actual content can diverge, and that purity varies between samples. Analytical laboratories use reversed-phase chromatography to separate components and mass spectrometry to confirm identity. Isotope-labeled internal standards improve quantification in complex matrices. Such methods describe what a sample contains but say nothing about its sterility, lawful status, or suitability for any use. Open questions remain about how consistently testing is applied across the supply chain.
Regulatory treatment of this peptide varies by country. It holds no marketing authorization as a medicine in the United States, the European Union, or most other jurisdictions. Some countries classify products containing it as prescription-only or unlicensed medicines, which restricts lawful supply. Authorities have issued public notices warning that unregulated products may contain undeclared or incorrect ingredients. The molecule also appears on prohibited lists for competitive sport. These measures address supply oversight rather than any approved therapeutic role.
| Property | Value | Notes |
|---|---|---|
| Common synonyms | Melanotan II; MT-II; N-acetyl-norleucyl-cyclo[Asp-His-D-Phe-Arg-Trp-Lys] amide | Naming follows peptide convention; the numeral distinguishes it from melanotan-1 |
| Molecular formula | C50H69N15O9 | Includes the lactam bridge; no counter-ion assumed |
| Monoisotopic mass | 1023.53 Da | Free base; salts and counter-ions shift the observed value |
| Appearance | White to off-white lyophilised powder | Batch-to-batch colour variation is not itself proof of impurity |
| Typical analytical method | RP-HPLC purity determination with ESI-MS identity confirmation | Retention time alone does not establish sequence identity |
The peptide was developed during the 1980s by researchers investigating melanocortin signalling and skin pigmentation pathways. Early work focused on analogues of alpha-melanocyte-stimulating hormone that would resist enzymatic breakdown more effectively than the parent molecule. Melanotan-2 emerged from that programme as a shortened, cyclised variant. Reports describing its synthesis and receptor activity later appeared in the scientific literature. Commercial availability grew through unregulated channels rather than through pharmaceutical approval.
Structurally, Melanotan-2 retains the core recognition motif of alpha-melanocyte-stimulating hormone while adding a lactam bridge that links two side chains and constrains the molecule into a ring. This modification lowers susceptibility to enzymatic degradation. The compound acts as an agonist at melanocortin receptors, particularly subtypes associated with melanin production. Because the same receptor family influences several physiological processes, researchers note that its activity is not confined to pigmentation alone. Receptor selectivity continues to be examined in published studies.
Regulatory treatment varies by country. In the United States the peptide is not approved as a medicine, and products offered for human use may be treated as unapproved new drugs; some states also restrict sale. Australia, the United Kingdom, and European Union member states apply comparable restrictions to unapproved peptide products. Border agencies have seized shipments labelled as research chemicals. Classification may change over time, and the legal position for personal importation is not clearly settled in most published guidance.
Lyophilised melanotan-2 is supplied as a solid, which is more stable than a solution. The material is hygroscopic, so weighing is done quickly, in low humidity, with the container kept sealed. Reconstitution usually uses water for injection or bacteriostatic water, added down the wall of the vial to limit foaming. A reconstituted solution is held at 2 to 8 °C and kept away from light. Repeated freezing and thawing of the same vial is avoided because ice crystal formation and concentration effects degrade the peptide.
Receptor-binding studies classify melanotan II as a non-selective melanocortin agonist. It interacts with MC1R, MC3R, MC4R and MC5R, with reported affinities in the low nanomolar range and no strong subtype preference. Activation of MC1R on dermal melanocytes shifts pigment synthesis toward eumelanin, the dark polymer deposited in melanosomes and transferred to keratinocytes. Because the same peptide engages MC4R in the hypothalamus, it also appears in animal work on food intake and erectile response, which is why it is discussed in both pigment and metabolic research. Which receptor populations dominate after systemic exposure in humans is not fully established.
Published pharmacokinetic information is limited and comes mainly from small studies rather than registrational trials. Plasma half-life is usually described as short, on the order of tens of minutes, followed by rapid tissue distribution and clearance of the intact peptide. Metabolites and low concentrations of parent compound have been reported in urine, a detail relevant to anti-doping and forensic testing. Whether repeated exposure changes receptor sensitivity or clearance over time remains an open question. Values differ noticeably between analytical assays, so published numbers should be read as approximate rather than definitive.
CG Cosmogenic nuclide. DP Naturally occurring decay product (of thorium-232, uranium-238, or uranium-235), including products of neutron reactions other than fission. ESS Present in the early Solar System (first few million years), but extinct now as a primordial nuclide. Inherently overlaps with cosmogenic nuclides. FP Nuclear fission product , may occur naturally from spontaneous fission. IM Industry or medically used radionuclide.
While the role of rain water δD as the fundamental control on the final δD of lipids is well documented, the importance of fractionation effects from rain water to soil water and leaf water on εl/w is appreciated but remains poorly understood. Organic biomolecules are generally depleted relative to the δD of leaf water. However, differences between organisms, biosynthetic pathways, and biological roles of different molecules can lead to huge variability in fractionation; the diversity of lipid biomarkers spans a 600‰ range of δD values. Lipid biosynthesis is biochemically complex, involving multiple enzyme-dependent steps that can lead to isotope fractionations. There are three major pathways of lipid biosynthesis, known as the mevalonate pathway, the acetogenic pathway, and the 1-deoxyD-xylulose-5-phosphate/2-methylerythroyl-4-phosphate pathway. The acetogenic pathway is responsible for the production of n-alkyl lipids like leaf waxes, and is associated with a smaller δD depletion relative to source water than the other two lipid biosynthesis pathways. While leaf water is the main source of hydrogen in leaf biomolecules, relatively depleted hydrogen from acetate or NADPH is often added during biosynthesis, and contributes to the HIC of the final molecule. Secondary hydrogen exchange reactions, meaning hydrogenation and dehydrogenation reactions outside of the primary biosynthetic pathway, also contribute substantially to the variability of lipid HIC.
It was also in the Basque Country where a higher percentage of negative votes was registered (23.5%). A different situation to that of Catalonia, where the level of participation was similar to that of the rest of Spain, and the positive votes exceeded 90%.
==== Saddle Nose ==== When performing a septoplasty as part of a rhinoplasty, it is recommended to leave an L-strut of at least 1cm. The L-strut is a dorsal and caudal portion of the septum that is preserved. If the septum is unsupported, the bridge of the nose can sink, resulting in a "saddle nose" deformity, usually caused by over-resection of the septal L-strut. This may necessitate structural reconstruction with autologous cartilage or bone grafts.
=== History === In January 2009, the U.S. Department of Defense announced the largest RFID award in history, a $429 million contract for DASH7 devices, to four prime contractors, namely Savi Technology, Northrop Grumman Information Technology, Unisys and Systems & Processes Engineering Corporation (SPEC). In March 2009, the DASH7 Alliance, a non-profit industry consortium to promote interoperability among DASH7-compliant devices, was announced, and as of July 2010 has more than 50 participants in 23 countries. It was meant to be similar to what the Wi-Fi Alliance does for IEEE 802.11, for wireless sensor networking. In April 2011, the DASH7 Alliance announced adoption of DASH7 Mode 2, based on the ISO 18000-7 standard that makes better use of modern silicon to achieve faster throughput, multi-hop, lower latency, better security, sensor support, and a built-in query protocol. In March 2012, the DASH7 Alliance announced that it was making the DASH7 Mode 2 specification available to non-members. In July 2013, the DASH7 Alliance announced the DASH7 Alliance Protocol Draft 0.2. In May 2015, the DASH7 Alliance publicly released v1.0 of the DASH7 Alliance Protocol. In January 2017, the DASH7 Alliance publicly released the v1.1 of the DASH7 Alliance Protocol. The version constitutes a major update of v1.0, in particular in the area of security and interoperability.
Sources: en.wikipedia.org
Although Christianity remains the single most popular religion in the United States, secularism has been growing thanks to Millennials and Generation Z. Among adults born between 2000 and 2006, only about a quarter prayed daily or attended religious service at least once a month. About twenty-nine percent were religiously unaffiliated. Americans who came of age during the 2020s were much more likely to have been raised in secular households. About three quarters of those who grew up in such an environment continued to be irreligious. Among those raised in highly religious households, just under a third still attended religious services regularly or thought of religion as important in their lives. While a slight majority of American teenagers attending public schools wore religious symbols and attire, they were much less likely to pray before lunch or a sport event, invite their peers to join a religious club, and to read religious texts outside of class. Girls were more likely to discuss religion with their friends than boys. Members of Generation Z were more likely to start questioning their parents' religions before the age of 18 than previous cohorts and those who have left typically did not return. Much of the decline of religion in the United States is due to people born after 1990 leaving their families' faiths. Young adults born in the 2000s rarely become Christian after being raised in a non-Christian household.
=== Data queries === Where data entered does not pass validation rules then a data query may be issued to the investigative site where the clinical trial is conducted to request clarification of the entry. Data queries must not be leading (i.e. they must not suggest the correction that should be made). For electronic CRFs only the site staff with appropriate access may modify data entries. For paper CRFs, the clinical data manager applies the data query response to the database and a copy of the data query is retained at the investigative site. When an item or variable has an error or a query raised against it, it is said to have a “discrepancy” or “query”. All EDC systems have a discrepancy management tool or also refer to “edit check” or “validation check” that is programmed using any known programming language (e.g. SAS, PL/SQL, C#, SQL, Python, etc). So what is a ‘query’? A query is an error generated when a validation check detects a problem with the data. Validation checks are run automatically whenever a page is saved “submitted” and can identify problems with a single variable, between two or more variables on the same eCRF page, or between variables on different pages. A variable can have multiple validation checks associated with it. Errors can be resolved in several ways:
==== FASTER ==== The FASTER algorithm uses a combination of deterministic and stochastic criteria to optimize amino acid sequences. FASTER first uses DEE to eliminate rotamers that are not part of the optimal solution. Then, a series of iterative steps optimize the rotamer assignment.
== Research == In addition to epilepsy, tiagabine was under formal clinical development for the treatment of anxiety disorders, insomnia, and neuropathic pain. However, development for all of these indications was discontinued. There have also been case reports and case series of tiagabine for treatment of bipolar disorder, though no clinical trials have been conducted. The drug has been studied for treatment of post-traumatic stress disorder (PTSD). It has been studied for treatment of aggression.
Sources: en.wikipedia.org
Following a hearing at the High Court, Mr Justice Linden rules that the nurses' strike planned for 30 April – 2 May is partially unlawful as it falls partly outside the six-month period from when members of the Royal College of Nursing voted to strike. The strike is cut short by a day as a consequence. The NHS COVID-19 contact tracing app closes down. 28 April – Richard Sharp resigns as chairman of the BBC over his breach of the BBC's rules regarding public appointments after failing to declare his connection to a loan secured by former prime minister Boris Johnson worth £800,000. 29 April Coronation of Charles III and Camilla: Organisers announce that among the changes to the ceremony for the coronation will be to invite people watching proceedings to swear allegiance to the King and his heirs. The service will also include female clergy and representatives from several different religions. The Guardian apologises following the publication of a cartoon depicting former BBC chairman Richard Sharp, who is Jewish, with exaggerated features and carrying a puppet of Rishi Sunak, after it was criticised for being antisemitic. The final UK rescue flight from the Sudanese capital of Khartoum takes off as the rescue of UK nationals comes to an end. Another flight from Port Sudan is subsequently arranged for 1 May. 30 April Eight people are stabbed, one fatally, in a street brawl near a nightclub in Bodmin, Cornwall. Police arrest a 24-year-old man on suspicion of murdering another man in his 30s. The deceased victim is subsequently named as Michael Allen, aged 32.
Notably, targeted proteomics shows increased reproducibility and repeatability compared with shotgun methods, although at the expense of data density and effectiveness. Data quality. Proteomic analysis is highly amenable to automation and large data sets are created, which are processed by software algorithms. Filter parameters are used to reduce the number of false hits, but they cannot be eliminated. Scientists have expressed the need for awareness that proteomics experiments should adhere to the criteria of analytical chemistry (sufficient data quality, sanity check, validation).
=== Conversion to esters, amides, anhydrides === Widely practiced reactions convert carboxylic acids into esters, amides, carboxylate salts, acid chlorides, acid anhydrides, and alcohols. Their conversion to esters is widely used, e.g. in the production of polyesters. Likewise, carboxylic acids are converted into amides, but this conversion typically does not occur by direct reaction of the carboxylic acid and the amine. Instead esters are typical precursors to amides. The conversion of amino acids into peptides is a significant biochemical process that requires ATP. Converting a carboxylic acid to an amide is possible, but not straightforward. Instead of acting as a nucleophile, an amine will react as a base in the presence of a carboxylic acid to give the ammonium carboxylate salt. Heating the salt to above 100 °C will drive off water and lead to the formation of the amide. This method of synthesizing amides is industrially important, and has laboratory applications as well. In the presence of a strong acid catalyst, carboxylic acids can condense to form acid anhydrides. The condensation produces water, however, which can hydrolyze the anhydride back to the starting carboxylic acids. Thus, the formation of the anhydride via condensation is an equilibrium process. Under acid-catalyzed conditions, carboxylic acids will react with alcohols to form esters via the Fischer esterification reaction, which is also an equilibrium process. Alternatively, diazomethane can be used to convert an acid to an ester.
In cardiac muscle, PKCε translocates to sarcomeres at Z-lines following α-adrenergic and endothelin (ET)A-receptor stimulation. A myriad of agonists have also been shown to induce the translocation of PKCε from the cytosolic to particulate fraction in cardiomyocytes, including but not limited to PMA or norepinephrine;arachidonic acid;ET-1 and phenylephrine; angiotensin II and diastolic stretch; adenosine; hypoxia and Akt-induced stem cell factor; ROS generated via pharmacologic activation of the mitochondrial potassium-sensitive ATP channel (mitoK(ATP)) and the endogenous G-protein coupled receptor ligand, apelin.
ubiquitination Also ubiquitylation. The labelling of a biomolecule (often another protein) by covalently attaching a ubiquitin protein to it—generally via the formation of an amide bond between the ubiquitin's C-terminal glycine and positively charged side chains (often lysine or arginine residues) of the labelled molecule, an ATP-dependent reaction catalyzed by ubiquitin-conjugating enzymes—thus making it identifiable to molecules capable of recognizing ubiquitin epitopes. Ubiquitination is a widely used post-translational modification by which proteins are tagged; the attachment of a single ubiquitin molecule (monoubiquitination) can variously activate or inhibit a protein's activity, while the attachment of a chain of multiple consecutively linked ubiquitin molecules (polyubiquitination) commonly targets the protein for degradation by proteasomes.
Sources: en.wikipedia.org
It is a synthetic cyclic heptapeptide analogue of alpha-melanocyte-stimulating hormone, containing seven amino acids with a lactam ring and a D-configured phenylalanine residue. It is supplied as a lyophilised powder for laboratory research.
The natural hormone is a linear tridecapeptide that is rapidly degraded in circulation. Melanotan-2 is shortened, cyclised, N-terminally acetylated, and carries a D-amino acid substitution, all of which slow enzymatic breakdown.
No national medicines regulator has approved melanotan-2 for therapeutic or cosmetic use. In several jurisdictions it is treated as an unapproved prescription medicine, and its legal classification differs from country to country.
Only a small number of early-stage human studies have been reported, and most were limited in size and duration. No large late-stage program has established a general efficacy or safety profile. The evidence base is therefore thin compared with approved medicines.